Spruce Biosciences Announces Topline Results From CAHmelia-204 In Adult CAH And CAHptain-205 In Adult And Pediatric CAH; Data Suggests Higher Doses And Twice-Daily Dosing May Be Necessary For Efficacy In CAH; Did Not Achieve Primary Endpoint Of...
Spruce Biosciences Announces Topline Results From CAHmelia-204 In Adult CAH And CAHptain-205 In Adult And Pediatric CAH; Data Suggests Higher Doses And Twice-Daily Dosing May Be Necessary For Efficacy In CAH; Did Not Achieve Primary Endpoint Of...
Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological and endocrine disorders with significant unmet medical need, today announced topline results from its CAHmelia-204 study of tildacerfont in adult CAH and its CAHptain-205 study of tildacerfont in adult and pediatric CAH.Spruce Biosciences Announces Topline Results From CAHmelia-204 In Adult CAH And CAHptain-205 In Adult And Pediatric CAH; Data Suggests Higher Doses And Twice-Daily Dosing May Be Necessary For Efficacy In CAH; Did Not Achieve Primary Endpoint Of Glucocorticoid Reduction; Evaluation Of Strategic Opportunities And Cost-Reduction Activities Underway
Spruce Biosciences发布了CAHmelia-204成人CAH和CAHptain-205成人及儿童CAH的顶线结果；数据表明，为了提高CAH的疗效，可能需要更高的剂量和每日两次给药；未能实现糖皮质激素减少的主要终点；正在评估战略机会和成本降低活动。
CAHmelia-204 Study of 200mg Once-Daily (QD) Tildacerfont in Adult Congenital Adrenal Hyperplasia (CAH) Did Not Achieve Primary Endpoint of Glucocorticoid (GC) Reduction
CAHmelia-204研究中，200mg每日一次（QD）的Tildacerfont未能实现糖皮质激素（GC）减少的主要终点。
Dose-Ranging Data from CAHptain-205 Study of Tildacerfont in Adult and Pediatric CAH Suggests Higher Doses and Twice-Daily (BID) Dosing May Be Necessary for Efficacy in CAH
从CAHptain-205研究中得到的剂量范围数据表明，在成人和儿童CAH患者中，Tildacerfont的更高剂量和每日两次（BID）给药可能是提高CAH的疗效所必需的。
Evaluation of Strategic Opportunities and Cost-Reduction Activities Underway
正在评估战略机会和成本降低活动。
Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological and endocrine disorders with significant unmet medical need, today announced topline results from its CAHmelia-204 study of tildacerfont in adult CAH and its CAHptain-205 study of tildacerfont in adult and pediatric CAH.
Spruce Biosciences, Inc.（纳斯达克：SPRB）是一家专注于开发和商业化针对神经和内分泌疾病的创新疗法的晚期生物制药公司，满足显著的医疗需求，今天发布了其成人CAH中Tildacerfont的CAHmelia-204研究及其成人和儿童CAH中Tildacerfont的CAHptain-205研究的顶线结果。
